Barlesi F - Search Results

1

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.

Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T, Grenier J. Pujol JL, et al. Among authors: barlesi f. Br J Cancer. 2004 Jun 1;90(11):2097-105. doi: 10.1038/sj.bjc.6601851. Br J Cancer. 2004. PMID: 15150567 Free PMC article.

2

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.

Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F, Kleisbauer JP. Barlési F, et al. Respir Med. 2004 Apr;98(4):357-62. doi: 10.1016/j.rmed.2003.11.003. Respir Med. 2004. PMID: 15080079 Free article.

3

[Prognostic indicators in stage I non-small cell lung cancer].

Barlési F, Doddoli C, Greillier L, Astoul P, Giudicelli R, Fuentes P, Thomas P. Barlési F, et al. Rev Mal Respir. 2004 Feb;21(1):93-103. doi: 10.1016/s0761-8425(04)71239-5. Rev Mal Respir. 2004. PMID: 15260042 Review. French.

4

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.

Barlési F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. Barlési F, et al. Br J Cancer. 2005 Jan 17;92(1):13-4. doi: 10.1038/sj.bjc.6602296. Br J Cancer. 2005. PMID: 15597098 Free PMC article.

5

Biologic staging of non-small-cell lung cancer: prospect or proposal?

Barlesi F, Jacot W, Pujol JL. Barlesi F, et al. Clin Lung Cancer. 2005 Jan;6(4):225-6. doi: 10.1016/S1525-7304(11)70471-5. Clin Lung Cancer. 2005. PMID: 15694014 No abstract available.

6

Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?

Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, Fuentes P, Thomas P. Doddoli C, et al. Among authors: barlesi f. Eur J Cardiothorac Surg. 2005 Apr;27(4):680-5. doi: 10.1016/j.ejcts.2004.12.035. Eur J Cardiothorac Surg. 2005. PMID: 15784374

7

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.

Barlési F, Pujol JL. Barlési F, et al. Lung Cancer. 2005 Sep;49(3):289-98. doi: 10.1016/j.lungcan.2005.03.034. Lung Cancer. 2005. PMID: 15913840

8

Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung.

Barlési F, Pinot D, Legoffic A, Doddoli C, Chetaille B, Torre JP, Astoul P. Barlési F, et al. Br J Cancer. 2005 Aug 22;93(4):450-2. doi: 10.1038/sj.bjc.6602717. Br J Cancer. 2005. PMID: 16052216 Free PMC article.

9

Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy.

Barlési F, Doddoli C, Torre JP, Giudicelli R, Fuentes P, Thomas P, Astoul P. Barlési F, et al. Eur J Cardiothorac Surg. 2005 Oct;28(4):629-34. doi: 10.1016/j.ejcts.2005.06.018. Eur J Cardiothorac Surg. 2005. PMID: 16125957

10

[A special issue of the Revue des Maladies Respiratoires dedicated to the courses of the Groupe d'Oncologie de Langue Française, in 2005].

Zalcman G, Barlesi F, Bréchot JM. Zalcman G, et al. Among authors: barlesi f. Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S5-7. Rev Mal Respir. 2005. PMID: 16340829 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters